Method for producing cardiomyocytes

By culturing somatic cells with specific low-molecular compounds, cardiomyocytes are directly induced from human fibroblasts without gene transfer, addressing limitations of existing methods and providing a scalable solution for cardiomyocyte production in regenerative medicine.

JP7586408B2Active Publication Date: 2024-11-19KYOTO PREFECTURAL PUBLIC UNIV CORP
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2019569055
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-01-30
Filing Date
2019-01-24
Publication Date
2024-11-19
Estimated Expiration
2039-01-24

AI Technical Summary

Technical Problem

Existing methods for directly converting human fibroblasts into cardiomyocytes require artificial gene transfer or the use of supernatants from cardiomyocytes derived from ES cells, limiting their applicability and efficiency.

Method used

A method involving the culture of somatic cells, particularly human fibroblasts, using a combination of low-molecular compounds such as MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, GR agonists, and ERK inhibitors to directly induce cardiomyocyte differentiation without gene transfer.

Benefits of technology

This approach allows for the production of spontaneously beating cardiomyocytes from somatic cells, which are useful in regenerative medicine, offering a scalable and efficient method for cardiomyocyte generation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586408000012
    Figure 0007586408000012
  • Figure 0007586408000013
    Figure 0007586408000013
  • Figure 0007586408000014
    Figure 0007586408000014
Patent Text Reader

Abstract

The main objective of the present invention is to provide a method for producing cardiomyocytes from somatic cells without artificial gene transfer, cardiomyocytes obtained by the production method, or a composition containing a combination of chemicals that can be used for the production method. The present invention can include, for example, a method for producing cardiomyocytes by directly inducing differentiation from somatic cells, which method comprises the step of culturing somatic cells in the presence of a MEK inhibitor and a cAMP inducer; cardiomyocytes obtained by the method; and a composition for producing cardiomyocytes from somatic cells by directly inducing differentiation, which composition comprises a MEK inhibitor and a cAMP inducer. The cardiomyocytes obtained by the present invention are useful in regenerative medicine and the like.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority based on Japanese Application No. 2018-13301, filed on January 30, 2018, the disclosure of which is incorporated herein in its entirety.

[0002] The present invention belongs to the technical field of regenerative medicine or direct reprogramming from somatic cells. In the technical field, the present invention relates to a method for directly producing cardiomyocytes from somatic cells using small molecule compounds, and to small molecule compound induced-cardiomyocytes (ciCMs) produced by such a production method. The present invention further relates to the cardiomyocytes and a composition that can be used for the method for producing the cardiomyocytes. [Background technology]

[0003] Due to recent developments in cell-related research, particularly in research on pluripotent cells, it is becoming possible to obtain therapeutic cells in a quality and quantity that can be used for transplantation into individuals. For some diseases, attempts have been started to transplant cells that are effective for treatment into patients.

[0004] Mesenchymal cells form various organs in the body, such as muscle, bone, cartilage, bone marrow, fat, and connective tissue, and are promising materials for regenerative medicine. Mesenchymal stem cells (MSCs) are undifferentiated cells present in tissues such as bone marrow, fat tissue, blood, placenta, and umbilical cord. Because they have the ability to differentiate into cells belonging to the mesenchymal system, mesenchymal stem cells have attracted attention as a starting material for producing such cells. In addition, regenerative medicine using mesenchymal stem cells themselves for the reconstruction of bone, cartilage, cardiac muscle, etc. is also being considered.

[0005] On the other hand, methods for directly converting somatic cells such as fibroblasts into other cells have also been reported. For example, it is known that nerve cells can be obtained by culturing fibroblasts with chemicals (Non-Patent Document 1). Cardiomyocytes are also known to be directly induced from mouse fetal fibroblasts by culturing them with certain chemicals, including a GSK3 inhibitor (CHIR99021) (Non-Patent Document 2). Similarly, cardiomyocytes are known to be directly induced from human foreskin fibroblasts (HFF) or fetal lung fibroblasts (HLF) (Non-Patent Document 3).

[0006] Patent Document 1 describes an invention for directly inducing cardiomyocytes from human fibroblasts using a composition containing at least five of a WNT agonist, a GSK3 inhibitor, a TGF-β inhibitor, an extracellular signal-regulated kinase (ERK1), a Ras GTPase activating protein inhibitor (Ras-GAP), an Oct-4 activator, a Rho-associated coiled-coil forming protein serine / threonine kinase inhibitor, an iron chelator, a KDM5B inhibitor, a histone methyltransferase inhibitor, and a PDGF tyrosine kinase inhibitor. Patent Document 2 describes an invention for directly inducing cardiomyocytes from human fibroblasts by culturing somatic cells in the presence of at least one inhibitor selected from the group consisting of an ALK6 inhibitor and an AMPK inhibitor, and in the presence of a cAMP activator, an ALK5 inhibitor (TGF-β inhibitor), and an ERK inhibitor. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] US Patent Application Publication No. 2016 / 0186141 [Patent Document 2] International Publication No. 2018 / 062269 [Non-patent literature]

[0008] [Non-Patent Document 1] Journal of Clinical Biochemistry and Nutrition,2015,Vol.56,No.3,pp.166-170 [Non-Patent Document 2] Cell Research, 2015, vol. 25, pp. 1013-1024 [Non-Patent Document 3] Science, 2016, volume 352, pages 1216-1220 Summary of the Invention [Problem to be solved by the invention]

[0009] A method for directly converting somatic cells into desired cells without gene transfer, such as the method described in Non-Patent Document 1, may be an effective option for obtaining therapeutic cells. As described above, cardiomyocytes are actually directly induced by culturing with a certain chemical substance, but in the invention described in Non-Patent Document 2, cardiomyocytes are directly induced from mouse fibroblasts, not from human fibroblasts. In addition, in the invention described in Non-Patent Document 3, cardiomyocytes are directly induced from human fibroblasts, but this requires the supernatant of cardiomyocytes differentiated from ES cells. In the inventions described in Patent Documents 1 and 2, cardiomyocytes are directly induced from human fibroblasts.

[0010] The main objective of the present invention is to provide a method for directly inducing cardiomyocytes from somatic cells without artificial gene introduction and using a combination of low molecular weight compounds different from the inventions described in Patent Documents 1 and 2, i.e., a new production method that can directly produce cardiomyocytes from somatic cells using a composition of certain low molecular weight compounds. [Means for solving the problem]

[0011] As a result of extensive research, the present inventors discovered that somatic cells can be directly converted into cardiomyocytes by culturing them in the presence of certain small molecule inhibitors, etc., and thus completed the present invention.

[0012] The present invention can include, for example, the following. [1] A method for producing cardiomyocytes by directly inducing differentiation from somatic cells, comprising a step of culturing somatic cells in the presence of a MEK inhibitor. [2] The method for producing cardiomyocytes described in [1] above, wherein the step further comprises culturing somatic cells in the presence of a cAMP inducer. [3] The method for producing cardiomyocytes described in [1] or [2] above, wherein the step further comprises culturing somatic cells in the presence of at least one selected from the group consisting of a TGF-β inhibitor, a PDE4 inhibitor, and a GR agonist. [4] The method for producing cardiomyocytes described in [3] above, wherein the step further comprises culturing somatic cells in the presence of an ERK inhibitor. [5] The method for producing cardiomyocytes described in any one of [1] to [3] above, wherein the step is a step of culturing somatic cells in the presence of any combination of the following (1) to (6): (1) MEK inhibitors, cAMP inducers, and TGF-β inhibitors, (2) MEK inhibitors, cAMP inducers, and PDE4 inhibitors, (3) MEK inhibitors, cAMP inducers, and GR agonists, (4) MEK inhibitors, cAMP inducers, PDE4 inhibitors, and GR agonists, (5) MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, and GR agonists, (6) MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, GR agonists, and ERK inhibitors. [6] The method for producing cardiomyocytes described in any one of [1] to [5] above, wherein the step is further a step of culturing somatic cells in the presence of at least one agent selected from the group consisting of an RAR agonist, an RXR agonist, and a PDK1 activator. [7] The method for producing cardiomyocytes according to any one of [1] to [6] above, wherein the MEK inhibitor is PD0325901. [8] The method for producing cardiomyocytes according to any one of the above [2] to [7], wherein the cAMP inducer is forskolin. [9] The method for producing cardiomyocytes described in any one of [3] to [8] above, wherein the TGF-β inhibitor is repxox, the PDE4 inhibitor is rolipram, or the GR agonist is dexamethasone.

[10] The method for producing cardiomyocytes according to any one of [4] to [9] above, wherein the ERK inhibitor is GDC-0994.

[11] A method for producing cardiomyocytes by directly inducing differentiation from somatic cells, comprising the steps of culturing somatic cells in the presence of a cAMP inducer, a TGF-β inhibitor, a PDE4 inhibitor, a GR agonist, and an ERK inhibitor.

[12] The method for producing cardiomyocytes described in

[11] above, wherein the cAMP inducer is forskolin, the TGF-β inhibitor is repsox, the PDE4 inhibitor is rolipram, the GR agonist is dexamethasone, or the ERK inhibitor is GDC-0994.

[13] The method for producing cardiomyocytes according to any one of [1] to

[12] above, wherein the somatic cells are fibroblasts.

[14] A cardiomyocyte produced by the method for producing a cardiomyocyte according to any one of [1] to

[13] above.

[0013]

[15] A composition for producing cardiomyocytes by directly inducing differentiation from somatic cells, the composition comprising a MEK inhibitor.

[16] The composition according to

[15] above, further comprising a cAMP inducer.

[17] The composition described in

[15] or

[16] above, further comprising at least one selected from the group consisting of a TGF-β inhibitor, a PDE4 inhibitor, and a GR agonist.

[18] The composition described in

[17] above, further comprising an ERK inhibitor.

[19] The composition according to any one of the above

[15] to

[18] , comprising any combination of the following (1) to (6): (1) MEK inhibitors, cAMP inducers, and TGF-β inhibitors, (2) MEK inhibitors, cAMP inducers, and PDE4 inhibitors, (3) MEK inhibitors, cAMP inducers, and GR agonists, (4) MEK inhibitors, cAMP inducers, PDE4 inhibitors, and GR agonists, (5) MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, and GR agonists, (6) MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, GR agonists, and ERK inhibitors.

[20] The composition according to any one of

[15] to

[19] above, further comprising at least one selected from the group consisting of an RAR agonist, an RXR agonist, and a PDK1 activator.

[21] The composition according to any one of

[15] to

[20] above, wherein the MEK inhibitor is PD0325901.

[22] The composition according to any one of

[16] to

[21] above, wherein the cAMP inducer is forskolin.

[23] The composition according to any one of the above

[17] to

[22] , wherein the TGF-β inhibitor is Repsox, the PDE4 inhibitor is Rolipram, or the GR agonist is dexamethasone.

[24] The composition according to any one of

[18] to

[23] above, wherein the ERK inhibitor is GDC-0994.

[25] A composition for producing cardiomyocytes by directly inducing differentiation from somatic cells, comprising a cAMP inducer, a TGF-β inhibitor, a PDE4 inhibitor, a GR agonist, and an ERK inhibitor.

[26] The composition described in

[25] above, wherein the cAMP inducer is forskolin, the TGF-β inhibitor is repsox, the PDE4 inhibitor is rolipram, the GR agonist is dexamethasone, or the ERK inhibitor is GDC-0994.

[27] The composition according to any one of

[15] to

[26] above, wherein the somatic cells are fibroblasts. Effect of the Invention

[0014] According to the present invention, spontaneously beating cardiomyocytes can be produced from somatic cells without gene transfer. The cardiomyocytes obtained by the present invention are useful in regenerative medicine and the like. [Brief description of the drawings]

[0015] [Figure 1] These are photographs of cell culture. In each photograph, the left side shows the results on the 7th day of culture, and the right side shows the results on the 10th day after the start of culture. [Diagram 2] These are photos of cell culture. In each photo, the left side shows the results after 7 days of culture, and the right side shows the results after 10 days of culture. [Diagram 3] These are photos of cell culture. In each photo, the left side shows the results after 7 days of culture, and the right side shows the results after 10 days of culture. [Figure 4] These are photographs of cell culture. In each photograph, the left side shows the results on day 7 of culture, and the right side shows the results on day 13 of culture. [Diagram 5] These are photographs of cell culture. In each photograph, the left side shows the results on day 7 of culture, and the right side shows the results on day 13 of culture. [Figure 6] Photographs of cell culture. The top two images show the results of culture at different locations for Example 7 on the 13th day, and the bottom two images show the results of culture at different locations for Example A on the 17th day. [Figure 7] The figure shows the relative expression level of mRNA. The left figure shows the expression level of myocardial progenitor cell-specific gene Tbx1 by each combination inhibitor, and the right figure shows the expression level of cardiomyocyte-specific gene Tnnt2 by each combination inhibitor. In each figure, the vertical axis shows the relative value of the amount of the mRNA to the amount of the internal standard gene (Tbp). [Figure 8] The figures show the relative expression levels of mRNA. The left figures show the expression levels of myocardial progenitor cell-specific genes by each combination of inhibitors, and the right figures show the expression levels of myocardial-specific genes by each combination of inhibitors. In each figure, the vertical axis shows the relative value of the amount of the mRNA to the amount of the internal standard gene (Tbp). [Figure 9] The left photo shows cells stained with Alpha Actinin / DAPI immunostaining, and the right photo shows a bright-field image superimposed on the left photo. [Figure 10] These are photographs of cell culture. The top three photographs show the results on the 13th day of culture, and the bottom three photographs show the results on the 19th day of culture. [Figure 11] These are photographs of cell culture. The top four photographs show the results on day 7 of culture, and the bottom four photographs show the results on day 12 of culture. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The present invention will be described in detail below.

[0017] 1. Method for producing cardiomyocytes The method for producing cardiomyocytes according to the present invention (hereinafter referred to as the "method of the present invention") is a method for producing cardiomyocytes by directly inducing differentiation from somatic cells, and is characterized by including a step of culturing somatic cells in the presence of a MEK inhibitor.

[0018] A preferred embodiment of the method of the present invention is a method of culturing somatic cells in the presence of a cAMP inducer. A more preferred embodiment of the method of the present invention is a method of culturing somatic cells in the presence of at least one selected from the group consisting of a TGF-β inhibitor, a PDE4 inhibitor, and a GR agonist. A more preferred embodiment of the method of the present invention is a method of culturing somatic cells in the presence of an ERK inhibitor. A particularly preferred embodiment of the method of the present invention is a method of culturing somatic cells in the presence of any combination of the following (1) to (6). (1) MEK inhibitors, cAMP inducers, and TGF-β inhibitors, (2) MEK inhibitors, cAMP inducers, and PDE4 inhibitors, (3) MEK inhibitors, cAMP inducers, and GR agonists, (4) MEK inhibitors, cAMP inducers, PDE4 inhibitors, and GR agonists, (5) MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, and GR agonists, (6) MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, GR agonists, and ERK inhibitors. The present invention also includes a method for producing cardiomyocytes by directly inducing differentiation from somatic cells, which is characterized by comprising a step of culturing somatic cells in the presence of a cAMP inducer, a TGF-β inhibitor, a PDE4 inhibitor, a GR agonist, and an ERK inhibitor. Hereinafter, such a production method is also referred to as the production method of the present invention.

[0019] In the above-mentioned step of the method of the present invention, the somatic cells can be further cultured in the presence of at least one agent selected from the group consisting of an RAR agonist, an RXR agonist, and a PDK1 activator. In the method of the present invention, somatic cells may be cultured in the presence of at least any of the above combinations, and if necessary, somatic cells may be cultured in the presence of other inhibitors, inducers, etc. to produce cardiomyocytes. The above inhibitors and inducers may each be used alone or in combination of two or more. Among the specific inhibitors, there may be those that have two or more types of inhibitory action, in which case one inhibitor can be regarded as having multiple inhibitors.

[0020] 1.1 About somatic cells The cells of an organism can be classified into somatic cells and germ cells. In the method of the present invention, any somatic cells can be used as the starting material. There is no particular limitation on the somatic cells, and they may be either primary cells collected from a living organism or cell lines. In the method of the present invention, somatic cells at various stages of differentiation, such as terminally differentiated somatic cells (e.g., fibroblasts, umbilical vein endothelial cells (HUVECs), hepatocytes, biliary cells, pancreatic α cells, pancreatic acinar cells, pancreatic ductal gland cells, intestinal crypt cells, etc.), somatic cells on the way to terminal differentiation (e.g., mesenchymal stem cells, neural stem cells, endodermal progenitor cells, etc.), or somatic cells that have been reprogrammed and acquired pluripotency can be used. Somatic cells that can be used in the method of the present invention include any somatic cells, such as hematopoietic cells (various types of lymphocytes, macrophages, dendritic cells, bone marrow cells, etc.), organ-derived cells (hepatocytes, spleen cells, pancreatic cells, kidney cells, lung cells, etc.), muscle tissue cells (skeletal muscle cells, smooth muscle cells, myoblasts, cardiac muscle cells, etc.), fibroblasts, nerve cells, osteoblasts, chondrocytes, endothelial cells, interstitial cells, adipocytes (brown adipocytes, white adipocytes, etc.), etc. The method of the present invention can also be applied to precursor cells of these cells and cancer cells. Fibroblasts can be preferably used.

[0021] Examples of sources of the above somatic cells include, but are not limited to, humans, non-human mammals, and non-mammalian animals (birds, reptiles, amphibians, fish, etc.). Preferred sources of somatic cells are humans and non-human mammals, and humans are particularly preferred. When producing cardiomyocytes by the method of the present invention for administration to humans, somatic cells collected from a donor having the same or similar histocompatibility antigen type as the recipient can be preferably used. Somatic cells collected from the recipient themselves may be used for producing cardiomyocytes.

[0022] 1.2 Inhibitors and the like according to the present invention 1.2.1 MEK inhibitors MEK (MAPK / ERK kinase) is a phosphorylating enzyme that belongs to the MAPK signaling pathway that is activated by growth factors such as EGF (epidermal growth factor), and in mammals, there are two genes encoded by MEK1 and MEK2. MEK is phosphorylated by the upstream RAF, and the activated MEK phosphorylates ERK to transmit signals further downstream. MEK inhibitors inhibit the phosphorylation of ERK, thereby inhibiting the MAPK signaling pathway mediated by MEK.

[0023] "In the presence of a MEK inhibitor" refers to culture conditions under which MEK, preferably MEK1 or MEK2, can be inhibited, and the means for inhibiting MEK are not particularly limited, and a substance that inhibits MEK activity, for example, a MEK signal inhibition means such as an anti-MEK antibody or a MEK inhibitor, can be used. In addition, a means for inhibiting a protein involved in MEK activation, for example, a cell membrane receptor such as EGFR located upstream of MEK in the MAPK signal transduction pathway, a small GTP-binding protein RAS, a phosphorylating enzyme RAF, etc., can also be used for MEK inhibition.

[0024] Although not particularly limited in the present invention, the following compounds can be used as MEK inhibitors. Preferably, PD0325901 and Trametinib can be used.

[0025] PD0325901(CAS No.:391210-10-9)

[0026] [ka]

[0027] Trametinib (CAS No.:871700-17-3) [ka]

[0028] U0126-EtOH(CAS No.:1173097-76-1) TAK-733 (CAS No.: 1035555-63-5) BI-847325(CAS No.:1207293-36-4) Honokiol (CAS No.: 35354-74-6) Myricetin (CAS No.: 529-44-2) AS703026(CAS No.:1236699-92-5) AZD8330(CAS No.:869357-68-6) CI-1040(CAS No.:212631-79-3) Cobimetirlib(CAS No.:934660-93-2) GDC-0623(CAS No.:1168091-68-6) MEK162 (CAS No.: 606143-89-9) PD318088(CAS No.:391210-00-7) PD98059(CAS No.:167869-21-8) Refametinib (CAS No.:923032-37-5) Selumetinib (CAS No.:606143-52-6) SL327(CAS No.:305350-87-2)

[0029] The concentration of the MEK inhibitor may be appropriately determined and is not particularly limited, but may be, for example, in the range of 0.1 μmol / L to 10 μmol / L, preferably 0.5 μmol / L to 5 μmol / L.

[0030] 1.2.2 cAMP inducers cAMP (cyclic adenosine monophosphate) is a substance that is involved in various intracellular signal transduction as a second messenger. cAMP is generated in cells by the cyclization of adenosine triphosphate (ATP) by adenylate cyclase.

[0031] "In the presence of a cAMP inducer" refers to culture conditions under which cAMP can be induced, and the means for induction are not particularly limited. For example, any means capable of increasing the intracellular cAMP concentration can be used. Substances capable of directly acting on and inducing adenylate cyclase, an enzyme involved in the production of cAMP, substances capable of promoting the expression of adenylate cyclase, as well as substances inhibiting phosphodiesterase, an enzyme that decomposes cAMP, can be used as means for increasing the intracellular cAMP concentration. Membrane-permeable cAMP analogs such as dibutyryl cAMP and 8-bromo-cAMP, which are structural analogs of cAMP that have the same action as cAMP in cells, can also be used.

[0032] Although not particularly limited in the present invention, examples of cAMP inducers (adenylate cyclase activators) include forskolin (CAS No.: 66575-29-9), forskolin derivatives (e.g., JP-A-2002-348243), and the following compounds. Forskolin can be preferably used.

[0033] Forskolin (CAS No.: 66428-89-5)

[0034] [ka]

[0035] Isoproterenol (CAS No.: 7683-59-2) NKH477(CAS No.:138605-00-2) PACAP1-27(CAS No.:127317-03-7) PACAP1-38(CAS No.:137061-48-4)

[0036] The concentration of the cAMP inducer may be appropriately determined and is not particularly limited, but may be, for example, in the range of 0.2 μmol / L to 50 μmol / L, preferably 1 μmol / L to 30 μmol / L.

[0037] 1.2.3 TGF-β inhibitors There are three types of TGF-β (transforming growth factor-β), TGF-β1, TGF-β2, and TGF-β3, which are produced by almost all cells. TGF-β is involved in a wide variety of cellular functions, including the control of cell proliferation, transformation, differentiation, development, and apoptosis, and inhibits the proliferation of many cells, including epithelial cells.

[0038] "In the presence of a TGF-β inhibitor" refers to culture conditions under which TGF-β can be inhibited, and the means for inhibiting TGF-β are not particularly limited, and any means for inhibiting TGF-β can be used. In the present invention, substances that directly act on TGF-β to inhibit its function (e.g., anti-TGF-β antibodies and other drugs), drugs that suppress the production of TGF-β itself, and the like can be used. TGF-β can also be inhibited by inhibiting upstream signal transduction involving TGF-β.

[0039] Although not particularly limited in the present invention, the following compounds can be used as TGF-β inhibitors. Preferably, Repsox can be used.

[0040] A83-01(CAS No.:909910-43-6)

[0041] [ka]

[0042] Repsox (CAS No.: 446859-33-2)

[0043] [ka]

[0044] SB431542(CAS No.:301836-41-9)

[0045] [ka]

[0046] LY364947(CAS No.:396129-53-6) SB525334(CAS No.:356559-20-1) SD208(CAS No.:627536-09-8) Galunisertib(LY2157299)(CAS No.:700874-72-2) LY2109761(CAS No.:700874-71-1) SB505124(CAS No.:694433-59-5) GW788388(CAS No.:452342-67-5) EW-7197(CAS No.:1352608-82-2)

[0047] The concentration of the TGF-β inhibitor may be appropriately determined and is not particularly limited, but may be, for example, in the range of 0.1 μmol / L to 30 μmol / L, preferably 0.5 μmol / L to 10 μmol / L.

[0048] 1.2.4 PDE4 inhibitors PDE4 (Phosphodiesterase-4) is a member of the phosphodiesterase superfamily. Phosphodiesterases are enzymes that hydrolyze phosphodiester bonds. In particular, PDE4 hydrolyzes the cyclic phosphodiester bond of cAMP, a second messenger in the signal transduction pathway, and plays an important role in regulating its intracellular concentration. PDE4 is present in immune cells, brain cells, and nerve cells.

[0049] "In the presence of a PDE4 inhibitor" refers to a culture condition that can inhibit PDE4, and the means are not particularly limited, and any means that can inhibit PDE4 can be used. In the present invention, a substance that directly acts on PDE4 to inhibit its function (e.g., anti-PDE4 antibody or other drug), a drug that suppresses the production of PDE4 itself, etc. can be used. In addition, PDE4 can also be inhibited by inhibiting the signal transduction involving PDE4 at its upstream.

[0050] Although not particularly limited in the present invention, the following compounds can be used as PDE4 inhibitors. Preferably, rolipram or its optical isomers (e.g., R(-) and S(+)) can be used.

[0051] Rolipram (CAS No.: 61413-54-5)

[0052] [ka]

[0053] Roflumilast(CAS No.:162401-32-3) Cilomilast(CAS No.:153259-65-5) GSK256066(CAS No.:801312-28-7) Apremilast(CC-10004)(CAS No.:608141-41-9)

[0054] The concentration of the PDE4 inhibitor may be appropriately determined and is not particularly limited, but may be, for example, in the range of 0.1 μmol / L to 20 μmol / L, preferably 0.5 μmol / L to 10 μmol / L.

[0055] 1.2.5 GR agonists GR (Glucocorticoid Receptor) belongs to the nuclear receptor superfamily and acts as a transcription factor that binds to the steroid hormone glucocorticoid and regulates its transcriptional activity. GR is widely expressed throughout the human body, and due to its functional importance, many synthetic agonists, such as dexamethasone, have been developed.

[0056] "In the presence of a GR agonist" refers to culture conditions under which GR can be activated, and the means for activation are not particularly limited, and any means for activating GR can be used. In the present invention, a substance that directly acts on GR to activate its function, a drug that promotes the expression of GR itself, etc. can be used. In addition, the function of GR can also be controlled by regulating a transcription factor or a transcription coactivator that interacts with GR, or by regulating the expression or post-translational modification of these factors.

[0057] Although not particularly limited in the present invention, the following compounds can be used as GR agonists, for example. Preferably, dexamethasone can be used.

[0058] Steroid compounds such as dexamethasone, betamethasone, prednisolone, prednisone, methylprednisolone, triamcinolone, beclomethasone, budesonide, hydrocortisone, cortisone acetate, GSK9027, fluticasone, and mometasone. A non-steroidal compound classified as a selective glucocorticoid receptor modulator or selective glucocorticoid receptor agonist.

[0059] The concentration of the GR agonist may be appropriately determined and is not particularly limited, but can be, for example, in the range of 0.01 μmol / L to 10 μmol / L, preferably 0.05 μmol / L to 2 μmol / L.

[0060] 1.2.6 RAR agonists, RXR agonists RAR (Retinoic acid receptor) belongs to the nuclear receptor superfamily, and its transcriptional activity is activated by retinoic acid as a ligand. RAR has various functions in the body, and since it is closely related to cell differentiation in particular, many artificial synthetic agonists have been developed. RXR (retinoid X receptor) belongs to the nuclear receptor superfamily, and like RAR, its transcriptional activity is regulated by ligands such as retinoic acid. RXR forms heterodimers with various nuclear receptors including RAR, and intricately regulates the transcriptional activity of its partner nuclear receptors through binding to specific base sequences and recruiting transcription coactivators.

[0061] "In the presence of an RAR agonist or an RXR agonist" refers to culture conditions under which RAR or RXR can be activated, and the means are not particularly limited, and any means capable of activating RAR or RXR can be used. In the present invention, a substance that directly acts on RAR or RXR to activate its function, a drug that promotes the expression of RAR or RXR itself, etc. can be used. In addition, the function of RAR or RXR can be controlled by regulating a transcription factor or a transcription coactivator that interacts with RAR or RXR, or the expression and post-translational modification of these factors.

[0062] Although not particularly limited in the present invention, the following compounds can be used as the RAR agonist or RXR agonist. Preferably, TTNPB, retinoic acid, CH55, and AM580 can be used.

[0063] TTNPB (Arotinoid acid, CAS No.: 71441-28-6)

[0064] [ka]

[0065] Retinoic acid (CAS No.: 302-79-4) Tretinoin (CAS No.: 302-79-4) Adapalene(CAS No.:106685-40-9) Bexarotene(CAS No.:153559-49-0) Tazarotene(CAS No.:118292-40-3) Tamibarotene(CAS No.:94497-51-5) CH55(CAS No.:110368-33-7) AM580 (CAS No.: 102121-60-8)

[0066] The concentration of the RAR agonist or RXR agonist may be appropriately determined and is not particularly limited, but may be, for example, in the range of 0.05 μmol / L to 10 μmol / L, preferably 0.5 μmol / L to 5 μmol / L.

[0067] 1.2.7 PDK1 activators PDK1 (phosphoinositide-dependent protein kinase-1) is a kinase that phosphorylates and activates AKT, and functions as the center of the inositol phospholipid-mediated signal transduction pathway. This PDK1 / AKT signal pathway plays an extremely important role in cell survival, proliferation, glucose and lipid metabolism, etc. PS48, a PDK1 activator, directly binds to PDK1 and phosphorylates AKT, activating this signal pathway.

[0068] "In the presence of a PDK1 activator" refers to culture conditions under which PDK1 can be activated, and the means for activating PDK1 are not particularly limited, and any means capable of increasing the intracellular PDK1 concentration can be used, for example. In addition, since PDK1 is activated by phosphatidylinositol triphosphate produced by activation of phosphoinositide 3-kinase (PI3K) via various receptors including tyrosine kinase receptors, cytokine receptors, and G protein-coupled receptors, substances that activate these receptors or other stimuli that induce the production of phosphatidylinositol triphosphate can also be used as a means for activating PDK1.

[0069] Although not particularly limited in the present invention, the following compounds can be used as PDK1 activators, for example. Preferably, PS48 can be used.

[0070] PS48((2Z)-5-(4-Chlorophenyl)-3-phenyl-2-pentenoic acid, CAS No.:1180676-32-7) OSU-03012(AR-12)(CAS No.:742112-33-0) BX795 (CAS No.: 702675-74-9) BX912 (CAS No.: 702674-56-4) PHT-427 (CAS No.: 1191951-57-1)

[0071] The concentration of the PDK1 activator may be appropriately determined and is not particularly limited, but may be, for example, in the range of 0.5 μmol / L to 30 μmol / L, preferably 1 μmol / L to 10 μmol / L.

[0072] 1.2.8 ERK inhibitors ERK (Extracellular Signal-regulated Kinase) is a subfamily of MAPK that is activated by EGF (epidermal growth factor), serum stimulation, or oxidative stress, and ERK is divided into ERK1 / 2, ERK5, ERK7, and ERK8 based on the difference in the signal transduction pathway involved. When a ligand binds to a tyrosine kinase receptor such as the epidermal growth factor receptor (EGFR), a signal flows, and the TEY motif in the activation loop of ERK is phosphorylated, activating it.

[0073] "In the presence of an ERK inhibitor" refers to culture conditions under which ERK can be inhibited, and the means for inhibiting ERK are not particularly limited, and a substance that inhibits ERK activity, for example, an anti-ERK antibody or an ERK inhibitor, can be used as a means for inhibiting ERK signaling. In addition, a means for inhibiting an enzyme involved in ERK activation, for example, an ERK kinase or an ERK kinase kinase, can also be used for ERK inhibition.

[0074] Although not particularly limited in the present invention, the following compounds can be used as ERK inhibitors. Preferably, GDC-0994 (Ravoxertinib) can be used.

[0075] GDC-0994(CAS No.:1453848-26-4)

[0076] [ka]

[0077] SCH772984(CAS No.:942183-80-4) MK-8353(SCH900353)(CAS No.:1184173-73-6) Magnolin (CAS No.: 31008-18-1) LY3214996(CAS No.:1951483-29-6) FR 180204(CAS No.:865362-74-9) AZD0364(CAS No.:2097416-76-5)

[0078] The concentration of the ERK inhibitor may be appropriately determined and is not particularly limited, but can be, for example, in the range of 0.1 μmol / L to 10 μmol / L, preferably 0.2 μmol / L to 5 μmol / L.

[0079] 1.3 Somatic cell culture In the method of the present invention, somatic cells may be cultured in the presence of the above-mentioned various inhibitors (and, in some cases, inducers or activators) by selecting the medium, temperature, and other conditions according to the type of somatic cells used. The medium may be selected from known or commercially available media. For example, common media such as MEM (minimum essential medium), DMEM (Dulbecco's modified Eagle's medium), DMEM / F12, or modified media thereof may be used by adding appropriate components (serum, proteins, amino acids, sugars, vitamins, fatty acids, antibiotics, etc.).

[0080] As the culture conditions, general cell culture conditions may be selected. Examples include conditions of 37°C and 5% CO2. It is preferable to change the medium at appropriate intervals during culture (preferably once every 1 to 7 days, more preferably once every 3 to 4 days). When the method of the present invention is carried out using fibroblasts as the material, cardiomyocytes appear in 5 to 8 days to 3 weeks under conditions of 37°C and 5% CO2. By selecting somatic cells that are easy to culture, it is also possible to convert somatic cells with an increased cell number into cardiomyocytes. Therefore, it is easy to produce scaled-up cardiomyocytes.

[0081] For the culture of somatic cells, cell culture containers such as plates, dishes, cell culture flasks, cell culture bags, etc. can be used. Note that gas-permeable cell culture bags are preferred. When a large amount of cells is required, a large culture tank may be used. The culture can be performed in either an open or closed system, but when the obtained cardiomyocytes are intended to be administered to humans, it is preferable to culture in a closed system. In the method of the present invention, somatic cells are cultured in a medium containing the various inhibitors and the like described above, thereby making it possible to produce cardiomyocytes from somatic cells in a single culture step.

[0082] In the method of the present invention, cardiomyocytes are produced from somatic cells. 5-azacytidine, angiotensin II, BMP-2 (Bone Morphogenetic Protein 2), dimethyl sulfoxide (DMSO), and the like are known to be effective substances for inducing differentiation into cardiomyocytes. As a substance effective for inducing differentiation into cardiomyocytes, for example, a commercially available differentiation inducer can also be used. In the present invention, somatic cells can be cultured in the presence of the above-mentioned substances.

[0083] 1.4 Cardiomyocytes A cell population containing cardiomyocytes can be obtained by the above-mentioned production method of the present invention. Cardiomyocytes produced by the production method of the present invention are also within the scope of the present invention. The cardiomyocytes produced by the production method of the present invention may be terminally differentiated cells or precursor cells destined to differentiate into cardiomyocytes. The cardiomyocytes produced by the method of the present invention are so-called small molecule compound-induced cardiomyocytes (ciCMs) that are directly induced from somatic cells by small molecule compounds, and are distinguished from cardiomyocytes induced to differentiate from ES cells or iPS cells. They are also distinguished from the small molecule compound-induced cardiomyocytes described in Patent Document 1 and the like, due to the difference in the small molecule compounds used.

[0084] Cardiomyocytes produced by the method of the present invention can be detected, identified and separated, for example, by utilizing morphological changes in the cells, characteristic properties of cardiomyocytes and specific markers. Cardiomyocytes have a unique characteristic of autonomous pulsation, which other cells do not have, and can be distinguished from other cells by observation under a microscope. Specific markers for cardiomyocytes include, but are not limited to, cardiac troponin C (cTnT), α-myosin heavy chain, α-actin, etc.

[0085] Specific markers can be detected by diagnostic methods (antibody detection), but protein molecules may be detected by quantifying the amount of mRNA. Antibodies that recognize specific markers of cardiomyocytes are also useful for isolating and purifying cardiomyocytes obtained by the method of the present invention.

[0086] The cardiomyocytes produced by the method of the present invention can be used, for example, for tissue repair. The cardiomyocytes produced by the method of the present invention can be used to produce a pharmaceutical composition for tissue repair. As a means of treating heart diseases such as heart failure or myocardial infarction, methods for producing cardiomyocytes and methods for transplanting cardiomyocytes have been developed. For example, myocardial sheets formed by laminating cardiomyocytes and endothelial cells show excellent therapeutic effects and engraftment properties, and are therefore expected to be used in the treatment of severe heart failure.

[0087] When the cardiomyocytes produced by the method of the present invention are used as a pharmaceutical composition, the cardiomyocytes may be mixed with a medicamentically acceptable carrier in a conventional manner to prepare a formulation suitable for administration to an individual. Examples of the carrier include saline, distilled water for injection made isotonic by adding glucose or other auxiliary drugs (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.). In addition, buffers (e.g., phosphate buffer, sodium acetate buffer), soothing agents (e.g., benzalkonium chloride, procaine hydrochloride, etc.), stabilizers (e.g., human serum albumin, polyethylene glycol, etc.), preservatives, antioxidants, etc. may be added. The cardiomyocytes produced by the method of the present invention can also be made into a composition in which they are combined with other cells or components that are effective in improving the function and engraftment of cardiomyocytes.

[0088] Furthermore, the cardiomyocytes produced by the method of the present invention can be used for screening of drug candidate compounds acting on cardiomyocytes and for evaluating the safety of drug candidate compounds. Cardiomyocytes are an important tool for evaluating the cardiotoxicity of drug candidate compounds. According to the method of the present invention, many cardiomyocytes can be obtained in a single operation, which makes it possible to obtain reproducible research results without being affected by differences in cell lots.

[0089] 2 Composition The composition according to the present invention (hereinafter referred to as "the composition of the present invention") is a composition for producing cardiomyocytes by directly inducing differentiation from somatic cells, and is characterized by containing a MEK inhibitor.

[0090] The composition of the present invention preferably further comprises a cAMP inducer. More preferably, the composition of the present invention further comprises at least one selected from the group consisting of a TGF-β inhibitor, a PDE4 inhibitor, and a GR agonist. More preferably, the composition of the present invention further comprises an ERK inhibitor. Particularly preferred is the composition of the present invention which contains any combination of the following (1) to (6). (1) MEK inhibitors, cAMP inducers, and TGF-β inhibitors, (2) MEK inhibitors, cAMP inducers, and PDE4 inhibitors, (3) MEK inhibitors, cAMP inducers, and GR agonists, (4) MEK inhibitors, cAMP inducers, PDE4 inhibitors, and GR agonists, (5) MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, and GR agonists, (6) MEK inhibitors, cAMP inducers, TGF-β inhibitors, PDE4 inhibitors, GR agonists, and ERK inhibitors. The present invention also includes a composition for producing cardiomyocytes by directly inducing differentiation from somatic cells, the composition comprising a cAMP inducer, a TGF-β inhibitor, a PDE4 inhibitor, a GR agonist, and an ERK inhibitor. Hereinafter, such a composition is also referred to as the composition of the present invention.

[0091] The composition of the present invention can further comprise at least one selected from the group consisting of an RAR agonist, an RXR agonist, and a PDK1 activator. The composition of the present invention may contain at least any of the combinations described above, and may further contain other inhibitors, inducers, and the like, as necessary. The above inhibitors and inducers may each be used alone or in combination of two or more. Among the specific inhibitors, there may be those that have two or more types of inhibitory action, in which case one may be regarded as containing a plurality of inhibitors. The specific examples and preferred examples of the inhibitors and inducers mentioned above are the same as those mentioned above.

[0092] The composition of the present invention can be used as a composition for producing cardiomyocytes from somatic cells. The composition of the present invention can also be used as a medium for producing cardiomyocytes from somatic cells.

[0093] An example of a medium used for producing cardiomyocytes from somatic cells is a basal medium produced by mixing components necessary for cell culture, and containing an MEK inhibitor, a cAMP inducer, and the like as active ingredients. The above-mentioned active ingredients may be contained at a concentration effective for producing cardiomyocytes, and the concentration can be appropriately determined by those skilled in the art. The basal medium can be selected from known media or commercially available media. For example, common media such as MEM (minimum essential medium), DMEM (Dulbecco's modified Eagle medium), DMEM / F12, or modified media thereof can be used as the basal medium.

[0094] The medium may further contain known medium components as described above in this specification, such as serum, proteins (albumin, transferrin, growth factors, etc.), amino acids, sugars, vitamins, fatty acids, antibiotics, etc.

[0095] The medium may further be supplemented with substances effective for inducing differentiation into cardiomyocytes, as described herein above.

[0096] Furthermore, in the present invention, by administering an MEK inhibitor and a cAMP inducer to a living body, cardiomyocytes can be produced from somatic cells in the living body. That is, according to the present invention, a method for producing cardiomyocytes from somatic cells in the living body is provided, which includes administering an MEK inhibitor and a cAMP inducer to a living body. Preferred combinations of inhibitors and the like to be administered to a living body are as described herein. Examples of living bodies include humans, non-human mammals, and non-mammalian animals (birds, reptiles, amphibians, fish, etc.), with humans being particularly preferred. By administering an MEK inhibitor and a cAMP inducer to a specific site in the living body, cardiomyocytes can be produced from somatic cells at the specific site. EXAMPLES

[0097] The present invention will be specifically described below with reference to examples and test examples, but the present invention is not limited to the scope of the following examples.

[0098] Example: Production of cardiomyocytes <Direct induction of cardiomyocytes from human fibroblasts> (1) Human fibroblasts The human fibroblasts used as the material were purchased from DS Pharma Biomedical Co., Ltd. The fibroblasts were derived from the skin of a 38-year-old human.

[0099] (2) Direct induction of cardiomyocytes from human fibroblasts Human fibroblasts were cultured at 8 × 10 4The cells were seeded one at a time and cultured in DMEM high glucose medium (Gibco) supplemented with 10% fetal bovine serum (FBS), 100 U / mL penicillin, and 100 μg / mL streptomycin at 37°C and 5% CO2 for 2 days (80-90% or more confluent). DMEM stands for Dulbecco's Modified Eagle Medium.

[0100] The medium in the above human fibroblast dish was replaced with DMEM (High Glucose) with L-Glutamine Phenol Red, Sodium Pyruvate (Gibco) supplemented with 20% fetal bovine serum (FBS), 2% B27-supplement (Gibco), 1% N2 (Gibco), non-essential amino acids (NEAA: Non-essential amino acids; Gibco), β-mercaptoethanol (Nacalai Tesque; final concentration 0.1 mmol / L), 2-phospho ascorbic acid (Sigma-Aldrich; final concentration 50 μg / mL), 100 U / mL penicillin, 100 μg / mL streptomycin, and the following low molecular weight compounds. After that, the medium was replaced with the same composition medium every 3 days, and the cells were cultured under 37°C and 5% CO2 conditions.

[0101] <Low molecular compounds> 2μM PD0325901(Cat#:162-25293,Wako) 15μM Forskolin (Cat#:063-02193, Wako) 5μM Repsox (Cat#:1894-25, BioVision) 3μM Rolipram (Cat#:180-01411, Wako) 1μM Dexamethasone (Cat#:047-18863, Wako) 1 μM retinoic acid (Cat#: 186-01114, Wako) 2μM TTNPB (Cat#:16144, Cayman Chemical) 10μM PS48(Cat#:164-25011, Wako)

[0102] (3) Results The results of the culture according to (2) above are shown in Tables 1 and 2, and Figures 1 to 6. In the tables, "+" indicates the presence of the compound in the medium, and "-" indicates the absence of the compound in the medium.

[0103] [Table 1]

[0104] [Table 2]

[0105] (4) Evaluation of cardiomyocytes In this experiment, cardiomyocyte-like cells appeared from about the fifth day after culturing with the addition of the low molecular weight compound. This was evaluated by observing the spontaneous and cyclic contraction of cell masses under a microscope. The photographs of the cells (Figs. 1-6) were taken 7 and 10 days (Figs. 1-3), 7 and 13 days (Figs. 4, 5), or 13 and 17 days (Fig. 6) after culturing with the addition of the low molecular weight compound.

[0106] In addition, for some of the combinations of low molecular weight compounds in Table 2, total RNA was extracted from the cells after 17 days of culture with the addition of the low molecular weight compound, and the expression levels of the cardiac progenitor cell-specific gene Tbx1 and the cardiac muscle cell-specific gene Tnnt2 were quantified by real-time PCR. The results are shown in Figure 7. Tbp in the figure indicates an internal standard gene, and the mRNA levels of Tbx1 and Tnnt2 were evaluated based on the relative values ​​of this mRNA level. The combination compounds of each symbol in the figure are as follows.

[0107] C: Control (no low molecular weight compound) M: Example A F: Comparative example 2 MF: Example 7 MF+Rep: Example 8 MF+Roli: Example 9 MF+Dex: Example 10 MF+Rep+Roli+Dex: Example 12

[0108] As is clear from Table 1 and the photographs in Figures 1 to 3, spontaneously contracting cell masses hardly appeared, especially when PD0325901 (MEK inhibitor) was removed from the combination of compounds. In addition, as is clear from Table 2 and the photographs in Figures 4 to 6, myocardial-like cell masses appeared, although the frequency was low, by adding PD0325901 (MEK inhibitor) and forskolin (cAMP inducer) or PD0325901 (MEK inhibitor) alone. In addition, as shown in the photograph in Figure 6, it was confirmed that spontaneously moving cell masses were generated not only in one place but in multiple places.

[0109] From Figure 7, it was found that the genes specific to cardiomyocytes were activated by each combination of compounds, compared to the expression levels of cells without the small molecule compounds. In particular, the expression of both genes was significantly increased by the combination of three compounds (PD0325901 (MEK inhibitor), forskolin (cAMP inducer), repsox (TGF-β)) and five compounds (PD0325901 (MEK inhibitor), forskolin (cAMP inducer), repsox (TGF-β), rolipram (PDE4 inhibitor), dexamethasone (GR agonist)).

[0110] From the results of this experiment, it was found that MEK inhibitors are important compounds for inducing cardiomyocytes, and that cardiomyocytes with good induction efficiency can be obtained by culturing at least in the presence of MEK inhibitors (e.g., PD0325901) or in combination with cAMP inducers (e.g., forskolin). In addition, when cultured in the presence of MEK inhibitors and cAMP inducers, as well as TGF-β inhibitors, PDE4 inhibitors, and GR agonists, the expression of the specific gene was significant.

[0111] Test Example 1 (1) Gene expression in cardiomyocytes Four types of compounds (4C), namely PD0325901 (MEK inhibitor), forskolin (cAMP inducer), repxox (TGF-β), and rolipram (PDE4 inhibitor), or a combination of five compounds, including these and dexamethasone (GR agonist), were added in the same manner as in the above examples, and cell culture was performed. After 18 days of culture, total RNA was extracted from the cells, and the expression levels of myocardial progenitor cell-specific genes Hand2 and Tbx1, and cardiomyocyte-specific genes Tnnt2, Nppa, and Nkx2.5 were quantified by real-time PCR. The results are shown in FIG. 8. In the figure, Tbp indicates a gene that serves as an internal standard, and the mRNA level of each gene is evaluated based on the relative value of this mRNA level. In the figure, "No compound" indicates the result when none of the compounds were added, and "4C+Dex" indicates the result when all of the above five compounds were added.

[0112] As is clear from FIG. 8, it was shown that direct induction from human dermal fibroblasts to cardiomyocytes was promoted by culturing with the addition of 4C or a compound group in which 4C was added with dexamethasone (GR agonist).

[0113] (2) Immunostaining In the above (1), the cells were cultured with the compound group consisting of 4C plus dexamethasone (GR agonist), and on the 18th day after culture, the cells were fixed with 4% paraformaldehyde and then immunostained. Anti-sarcomeric Alpha Actinin antibody (ab9465, Abcam; used at 200-fold dilution) was used for staining. The results are shown in Figure 9. In the figure, red indicates the staining result of Alpha Actinin, and blue indicates nuclear staining with DAPI (4',6-diamidino-2-phenylindole). Note that Figure 9 is displayed in gray, so red and blue are not displayed, but red and blue are displayed in the actual original photograph.

[0114] As shown in Figure 9, after culturing with the addition of the compounds, a certain number of cardiomyocytes were stained with Alpha Actinin, and staining was observed in the cytoplasm, rather than the cell nuclei, which were stained with DAPI. Expression of Alpha Actinin, a marker for cardiomyocytes, was observed in some cells, and the results of immunostaining also showed that culturing with the addition of the compounds directly induced human dermal fibroblasts to become cardiomyocytes.

[0115] Test Example 2 The following combinations of low molecular weight compounds were added and cell culture was carried out in the same manner as in the above examples. The state of the cells on days 13 and 19 after culture with the addition of the compounds is shown in FIG. In FIG. 10, "5C" represents a combination of five compounds other than Trametinib among the six low molecular weight compounds listed below, and the two photographs on the left side show the results of the culture with the addition of this compound group. "5C-M" represents a compound group in which PD0325901 (MEK inhibitor) is removed from the compound group of 5C, and the two photographs in the middle show the results of the culture with the addition of this compound group. "5C-M+Trametinib" represents a compound group in which PD0325901 (MEK inhibitor) is removed from the compound group of 5C and another MEK inhibitor, Trametinib, is added, and the two photographs on the right side show the results of the culture with the addition of this compound group.

[0116] <Low molecular compounds> 2μM PD0325901(Cat#:162-25293,Wako) 15μM Forskolin (Cat#:063-02193, Wako) 5μM Repsox (Cat#:1894-25, BioVision) 3μM Rolipram (Cat#:180-01411, Wako) 1μM Dexamethasone (Cat#:047-18863, Wako) 3μM Trametinib (Cat#:HY-10999,MedChem Express)

[0117] As is clear from FIG. 10, it was shown that the MEK inhibitor is important for the direct induction of cardiomyocytes from human dermal fibroblasts.

[0118] Test Example 3 The following combinations of low molecular weight compounds were added and cultured in the same manner as in the above Examples. The state of the cells on days 7 and 12 after culture following the addition of the low molecular weight compounds is shown in FIG. In FIG. 11, "5C" represents a combination of five compounds other than GDC-0994 among the six low molecular weight compounds listed below, and the two leftmost photographs show the results of the culture with the compounds added. "5C-M" represents a compound group obtained by removing PD0325901 (MEK inhibitor) from the compound group of 5C, and the second two photographs from the left show the results of the culture with the compounds added. "5C-M+GDC-0994" represents a compound group obtained by removing PD0325901 (MEK inhibitor) from the compound group of 5C and adding GDC-0994 (ERK inhibitor) instead, and the second two photographs from the right show the results of the culture with the compounds added. "5C+GDC-0994" represents a compound group obtained by adding GDC-0994 (ERK inhibitor) to the compound group of 5C, and the two rightmost photographs show the results of the culture with the compounds added.

[0119] <Low molecular compounds> 2μM PD0325901(Cat#:162-25293,Wako) 15μM Forskolin (Cat#:063-02193, Wako) 5μM Repsox (Cat#:1894-25, BioVision) 3μM Rolipram (Cat#:180-01411, Wako) 1μM Dexamethasone (Cat#:047-18863, Wako) 3μM GDC-0994 (Cat#:21107, Cayman Chemical)

[0120] As shown in Figure 11, direct induction of cardiomyocytes from human dermal fibroblasts was possible in the presence of an ERK inhibitor even in the absence of a MEK inhibitor, and it was also found that the presence of both a MEK inhibitor and an ERK inhibitor promoted the direct induction of cardiomyocytes from human dermal fibroblasts.

Claims

1. A method for producing cardiomyocytes by directly inducing differentiation from fibroblasts, comprising a step of culturing fibroblasts as a starting material in the presence of two agents, PD0325901 or trametinib as a MEK inhibitor and forskolin as a cAMP inducer, and at least one agent, rolipram as a PDE4 inhibitor, and dexamethasone as a GR agonist.

2. The method for producing cardiomyocytes according to claim 1 , wherein the step further comprises culturing fibroblasts in the presence of Repsox as a TGF-β inhibitor.

3. The method for producing cardiomyocytes according to claim 1 or 2, wherein the step further comprises culturing fibroblasts in the presence of GDC-0994 as an ERK inhibitor.

4. The method for producing cardiomyocytes according to any one of claims 1 to 3, wherein the step is a step of culturing fibroblasts in the presence of at least one selected from the group consisting of TTNPB or retinoic acid as an RAR agonist or RXR agonist, and PS48 as a PDK1 activator.

5. A method for producing cardiomyocytes by directly inducing differentiation from fibroblasts, comprising the step of culturing fibroblasts as a starting material in the presence of forskolin as a cAMP inducer, lepsox as a TGF-β inhibitor, rolipram as a PDE4 inhibitor, dexamethasone as a GR agonist, and GDC-0994 as an ERK inhibitor.

6. A composition for producing cardiomyocytes by directly inducing differentiation from fibroblasts, the composition comprising two agents, PD0325901 or trametinib as a MEK inhibitor and forskolin as a cAMP inducer, and at least one agent, rolipram as a PDE4 inhibitor and dexamethasone as a GR agonist.

7. The composition of claim 6, further comprising Repsox as a TGF-β inhibitor.

8. The composition according to claim 6 or 7, further comprising GDC-0994 as an ERK inhibitor.

9. The composition according to any one of claims 6 to 8, further comprising at least one selected from the group consisting of TTNPB or retinoic acid as an RAR agonist or RXR agonist, and PS48 as a PDK1 activator.

10. A composition for producing cardiomyocytes by directly inducing differentiation from fibroblasts, comprising forskolin as a cAMP inducer, lepsox as a TGF-β inhibitor, rolipram as a PDE4 inhibitor, dexamethasone as a GR agonist, and GDC-0994 as an ERK inhibitor.

Citation Information

Patent Citations

  • Method for producing mesenchymal cell

    JP2017104091A

  • Small molecule cellular reprogramming to generate cardiomyocytes

    US20160186141A1

  • Method for producing somatic cell, somatic cell, and composition

    WO2018062269A1